

Supplemental Material

Overweight and Obesity are Predictors of Progression in Early ADPKD

Kristen L Nowak, Zhiying You, Berenice Gitomer, Godela Brosnahan, Vincente E Torres, Arlene B Chapman, Ronald D Perrone, Theodore I Steinman, Kaleab Z Abebe, Frederic F Rahbari-Oskoui, Alan Yu, Peter C Harris, Kyongtae T Bae, Marie Hogan, Dana Miskulin, Michel Chonchol

Supplemental Table 1. Baseline characteristics of study participants from HALT Study A included in estimated glomerular filtration rate analyses according to body-mass index category.

Variable	Normal Weight (BMI 18.5-24.9 kg/m ²) (n=194)	Overweight (BMI 25-29.9 kg/m ²) (n=168)	Obese (BMI ≥30 kg/m ²) (n=86)	P-Value
Age (y)	37±9	38±7	36±9	0.07
Sex (% Male)	40.7%	65.5%	51.2%	<0.0001
Race (% White)	93.8%	94.0%	94.2%	0.99
Study BP Target Randomization Group (% low)	49.0%	49.4%	53.5%	0.78
Study BP Medication Randomization Group (% ACEi + ARB)	46.9%	50.0%	52.3%	0.67
CKD-EPI eGFR, ml/min/1.73m²	92.8±16.9	88.5±17.3	90.3±18.3	0.11
SBP (mmHg)	124±14	129±13	129±15	<0.001
BMI (kg/m²)	22.0±1.7	27.4±1.4	34.1±3.7	<0.0001
Urinary albumin (mg/24 hr)	18.3 (11.9-35.2)	17.3 (12.2-27.4)	19.6 (11.0-33.3)	0.54
Fasting serum glucose (mg/dL)	88±10	94±10	92±10	<0.0001
Mutation Class (%)				0.14
PKD1 truncating	51.3%	45.7%	39.5%	
PKD1 non-truncating	20.9%	32.3%	32.3%	
PKD2	18.2%	16.5%	17.4%	
No mutation detected	9.6%	5.5%	10.5%	

Data are mean±S.D., %, or median (IQR). ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CKD-EPI, chronic kidney disease epidemiology collaboration equation; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; BMI, body mass-index. BMI is calculated from body weight adjusted to remove the contribution of the liver and kidney to total weight. Mutation class is unavailable in n=11.